Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.55 (5.07%)
Data as of 04/24/18 4:00 p.m. ET

Latest News

Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024
Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.